July 26, 2016
July 25, 2016
Smaller or more niche-oriented players are hawking their wares to investors who want to allocate to activists but may be put off by the recent performance of big-name players.
July 22, 2016
July 21, 2016
Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?
July 20, 2016
July 19, 2016
July 18, 2016
Will Herbalife's share price fall after it implements the changes mandated by its settlement with the FTC?
View previous results
All material subject to strictly enforced copyright laws. ©
Euromoney Institutional Investor PLC.
Sorry, you are not allowed to print this article.
Please contact us if you have any inquiry.